Wolverine Trading
PGNX

Wolverine Trading’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Wolverine Trading’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-28,300
Closed -$144K – 5666
2019
Q4 		$144K Sell
28,300
-600
-2% -$3.17K ﹤0.01% 4172
2019
Q3 		$152K Sell
28,900
-3,900
-12% -$19.4K ﹤0.01% 3715
2019
Q2 		$202K Buy
32,800
+1,500
+5% +$7.23K ﹤0.01% 3717
2019
Q1 		$145K Buy
31,300
+5,200
+20% +$23.5K ﹤0.01% 4007
2018
Q4 		$106K Sell
26,100
-10,000
-28% -$50.9K ﹤0.01% 3968
2018
Q3 		$226K Buy
36,100
+9,700
+37% +$74.5K ﹤0.01% 4102
2018
Q2 		$197K Hold
26,400
– – ﹤0.01% 4390
2018
Q1 		$197K Buy
26,400
+14,100
+115% +$93.8K ﹤0.01% 4390
2017
Q4 		$73K Sell
12,300
-20,500
-63% -$125K ﹤0.01% 4535
2017
Q3 		$241K Sell
32,800
-3,000
-8% -$19.1K ﹤0.01% 3573
2017
Q2 		$249K Sell
35,800
-13,400
-27% -$98.9K ﹤0.01% 3314
2017
Q1 		$472K Buy
49,200
+38,600
+364% +$385K ﹤0.01% 2459
2016
Q4 		$92K Sell
10,600
-8,000
-43% -$59.1K ﹤0.01% 4082
2016
Q3 		$106K Buy
+18,600
New +$112K ﹤0.01% 4164

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wolverine Trading's PGNX Position: Q1 2020 in Review

Wolverine Trading sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2020, closing a stake of 18,938 shares — an estimated $96K sold.

Wolverine Trading first reported a position in PGNX in Q3 2016 and held it in 9 quarters. The position peaked at $152K in Q2 2017. 129 funds tracked by Wall St. Rank hold PGNX as of Q1 2020.

  • Wolverine Trading reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2020 after selling out during the quarter.
  • Wolverine Trading sold 18,938 Progenics Pharmaceuticals Inc shares in Q1 2020, an estimated $96K.
  • Wolverine Trading first reported a position in Progenics Pharmaceuticals Inc in Q3 2016 and held it in 9 quarters.
  • Wolverine Trading's Progenics Pharmaceuticals Inc position peaked at $152K in Q2 2017.
  • 129 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2020.

Based on Wolverine Trading's 13F filing for Q1 2020, filed 11 May 2020.